ArticleJournal of thrombosis and thrombolysis2026
Admission electrocardiographic markers of atrial cardiomyopathy predict persistent pulmonary hypertension and chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a retrospective cohort study.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent pulmonary hypertension (PH) and chronic thromboembolic pulmonary hypertension(CTEPH) are important complications after acute pulmonary embolism(PE), yet early risk stratification remains limited. We evaluated whether admission electrocardiographic markers of atrial cardiomyopathy are associated with 3-month persistent PH and confirmed CTEPH. This single-center retrospective cohort included 1,579 consecutive adults with computed tomography pulmonary angiography-confirmed acute PE between August 2018 and August 2025. All underwent admission electrocardiography and structured 3-month echocardiographic reassessment.The primary outcome was persistent PH, defined as intermediate/high echocardiographic PH probability at 3 months; the secondary outcome was confirmed CTEPH.The sinus rhythm subset was defined a priori for evaluating P-wave-based markers, including P-wave indices, P-terminal force in lead V1 (PTFV1), and interatrial block. Persistent PH occurred in 292 patients (18.5%), and confirmed CTEPH in 44 (2.8%). Because CTEPH work-up was mainly triggered by intermediate/high echocardiographic PH probability, confirmed CTEPH was ascertained within the persistent PH group. In the sinus rhythm subset, persistent PH was associated with longer P-wave duration, greater dispersion, higher PTFV1, and more frequent interatrial block (all p < 0.001). After adjustment, PTFV1 (OR 1.21 per 10 mm·ms, 95% CI 1.14-1.29; p < 0.001) and interatrial block (OR 1.78, 95% CI 1.28-2.49; p = 0.001) remained independently associated with persistent PH and confirmed CTEPH. Among acute PE survivors in sinus rhythm, P-wave-based ECG markers of atrial cardiomyopathy, particularly PTFV1 and interatrial block, were independently associated with persistent PH and confirmed CTEPH. These exploratory risk-enrichment markers are not applicable to non-sinus rhythms and require external validation.
Indexed as
Identifiers
42538479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.